MedTrace Logo

North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health

NCT07746999 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-08-05

No results posted yet for this study

Summary

Primary Objective:

Assess disparities in liver health outcomes among transgender individuals on GAHT by evaluating liver function markers (transaminases, bilirubin levels, etc), as well as liver elasticity and presence of liver steatosis or Nonalcoholic Fatty Liver Disease (NAFLD) through FibroScan. A total of 60 participants will be recruited throughout the study, with a ratio of 1:1 between transgender participants who have been on GAHT more than 6 months ( = or \> 182 days), and transgender participants who have been on GAHT for less than 6 months ( \< 181 days) at the start of the study.

Secondary Objectives:

Assess liver health-related risk factors (e.g. obesity, alcohol consumption) in transgender population.

Investigate the association between specific hormone regimens and liver function in transgender individuals.

Explore potential modifiers of liver health outcomes, such as age, social barriers determinants of health, duration of hormone therapy and adherence to medical guidelines.

Change in Quality of Life from baseline to last study visit.

Conditions

  • HEPATITIS C (HCV)

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)

    collaborator OTHER

  • Corey DeStefano

    lead OTHER

Principal Investigators

  • Diana Finkel, DO · North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-15
Primary Completion
2027-03-15
Completion
2027-03-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07746999 on ClinicalTrials.gov